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The report by Ahmed and col-
leagues opens up new possibilities for 
the treatment of chronic viral infections. 
Chronic viral infections are resistant to 
conventional medications and some-
times lead to tumorigenesis, such as 
liver cancer due to infections by HBV 
and hepatitis C virus. The invention of 
a safe and effective therapy is urgently 
needed. Interestingly, PD-1 deficiency 
leads to a relatively mild phenotype 
when compared to loss of another 
CD28 family member, CTLA-4, even 
though engagement of CTLA-4, like 
PD-1, results in the inhibition of T cell 
function. Also, the expression of PD-1 
is restricted to activated lymphocytes. 
Thus, blocking PD-1 may have fewer 
side effects than other potential thera-
pies. The next step may be to demon-
strate in human patients that antigen-
specific T cells survive during chronic 
infections, express PD-1, and are 
reanimated by blocking PD-1 signaling. 
Such findings could one day lead to 
the clinical use of PD-1 blockers for the 
treatment of chronic viral infections.
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Before launching a missile, it is necessary to design an efficient safety net for self-protection. 
In this issue of Cell, Ellermeier et al. (2006) describe the mechanism underlying a biological 
safety net for the soil bacterium Bacillus subtilis. This bacterium protects itself from a toxic 
protein it secretes by upregulating an immunity protein, which it does by sequestering a 
transcriptional repressor at the plasma membrane.When hungry, eat your sister... but 
beware that she does not eat you first! 
This is the motto of the soil bacterium 
Bacillus subtilis, according to results 
from Rich Losick’s lab, first reported 
by González-Pastor et al. (2003), and 
now further analyzed by Ellermeier et 
al. (2006) in this issue of Cell. When B. 
subtilis is subjected to starvation, two 
independant gene clusters become 
transcribed, leading to the synthesis 
and release in the external medium of 
two toxic peptides, SkfA and SdpC. Both factors kill neighboring siblings, 
thereby releasing nutrients that sus-
tain further growth of the bacteria pro-
ducing the toxins. However, in order to 
survive, these bacteria have to protect 
themselves from the toxic peptides 
they produce. The SkfA killing factor 
is pumped out of the bacterial cells 
by the products of two genes belong-
ing to the skf operon (González-Pas-
tor et al., 2003). In this issue of Cell, 
Ellermeier et al. (2006) elucidate the 
mechanism that provides protection Cell 124, Fagainst the SdpC peptide and reveal 
a remarkable new signal transduction 
pathway (see Figure 1).
The core of the new signaling path-
way is an operon encoding a soluble 
DNA binding protein, SdpR, and a 
transmembrane immunity protein, 
SdpI. When nutrients are plentiful, 
the sdpRI operon is not transcribed, 
due to the presence of the global 
repressor AbrB, which also represses 
the operon encoding the SdpC toxin 
(Fujita et al., 2005). As nutrients ebruary 10, 2006 ©2006 Elsevier Inc. 461
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tor, Spo0A, is activated and shuts off 
further synthesis of AbrB. Disappear-
ance of AbrB leads to the synthesis 
of the three proteins, SdpR, SdpI, and 
SdpC. Results from the González-
Pastor et al. (2003) and Ellermeier 
et al. (2006) studies suggest that the 
sdpRI operon is transcribed earlier 
than sdpC, presumably as a conse-
quence of the respective affinities of 
AbrB for the two promoter regions. 
However, because SdpR binds to 
the sdpRI promoter, transcription of 
sdpRI remains limited and only a few 
SdpI molecules are synthesized and 
inserted into the cytoplasmic mem-
brane. The SdpC toxin is secreted 
into the extracellular milieu and a 
striking switch occurs when it accu-
mulates in the external medium. The 
SdpI immunity protein, presumably 
by binding to the SdpC toxin, triggers 
sequestration of the SdpR autore-
pressor at the bacterial membrane. 
The redistribution of the SdpR pro-
tein from DNA to the membrane was 
directly visualized by Ellermeier et al. 
(2006). Sequestration of SdpR pro-
motes a high level of transcription of 
sdpRI, thereby increasing the amount 
of immunity protein for self-protection. 
Once active Spo0A reaches a critical 
concentration, it represses further 
transcription of the operon encoding 
SdpC (Fujita et al., 2005). The SdpC 
molecules become too scarce to bind 
figure 1. Toxin-Producing Bacillus 
subtilis Makes Only as Much Immunity 
Protein as It needs
The sdpRI operon (green and blue straight 
arrows) encodes the cytoplasmic SdpR au-
torepressor (green) and the membrane-bound 
SdpI immunity protein (blue), whereas the toxin-
 encoding gene sdpC is part of a separate oper-
on (red straight arrow). Transcription from sd-
pRI is induced by starvation and repressed by 
SdpR (thin arrow). Starved B. subtilis cells (rod 
shaped) also transcribe sdpC (medium arrow) 
and secrete the extracellular SdpC toxin (red). 
SdpC binds to SdpI, thereby triggering seques-
tration of SdpR at the membrane and activat-
ing sdpRI transcription (thick arrow). Increasing 
amounts of SdpI and SdpR molecules trap all 
SdpC molecules. Free SdpI cannot sequester 
SdpR, which remains in the cytoplasm, where 
it shuts off transcription of sdpRI (thin arrow). 
Transcription of sdpC is shut off once the global 
regulator Spo0A, which initiates this pathway in 
response to starvation, reaches a critical con-
centration.lsevier Inc.to all SdpI immunity molecules. Then, 
free SdpR autorepressor accumulates 
in the cytoplasm, effectively shutting 
off new synthesis of SdpR and SdpI. 
Therefore, production of the immunity 
protein strictly correlates, both in time 
and in amount, to the presence of the 
toxin protein in the growth medium.
The whole pathway is under the 
control of the master regulator Spo0A, 
whose activity increases as nutrients 
become more and more limiting, trig-
gering the successive activation or 
repression of several gene classes 
(Fujita et al., 2005). The complex 
mechanisms transducing metabolic 
imbalance into activation of Spo0A 
lead to heterogeneous populations 
of bacteria where individual cells 
have different levels of active Spo0A 
(Chung et al., 1994; Fujita and Losick, 
2005). Ultimately, the cells embark on 
an irreversible developmental proc-
ess culminating in the formation of a 
resting spore. The starved cells delay 
their commitment to sporulation by 
releasing SdpC (and the other kill-
ing factor SkfA) in the medium and, 
being fully armored to resist the tox-
icity of these two proteins, cannibal-
ize their unlucky sister cells that are 
lagging behind in activating Spo0A. 
This is the last supper that precedes 
the metamorphosis of the toxin-pro-
ducing bacteria into spores that may 
remain dormant for a very long time.
The SdpC toxin is synthesized as 
a larger cytoplasmic protein whose 
maturation into its extracellular active 
form requires the products of two 
genes cotranscribed with sdpC. A 
similar strategy is observed with col-
icins, proteins that are synthesized in 
an inactive form by some Escherichia 
coli strains and are secreted in the 
medium where they kill nonimmune 
neighboring bacteria. Presumably, this 
two-step process has been selected 
in order to avoid self-destruction of 
the toxin-producing bacteria. What 
would be the phenotype of B. subti-
lis cells producing the mature form of 
SdpC in their cytoplasm? Assuming 
such an experiment is feasible, would 
mature SdpC be toxic, from the inside, 
to the cells engineered to produce it? 
The molecular basis of SdpC toxicity 
remains obscure. It involves neither 
SdpI nor SdpR, although these two 
proteins were identified when search-
ing for targets of SdpC (González-
Pastor et al., 2003). If SdpC only acts 
on certain membrane proteins, it will 
only affect bacteria displaying these 
specific receptors, thereby limiting its 
toxicity to B. subtilis or very closely 
related bacteria. Conversely, if SdpC 
acts merely by inserting itself into the 
plasma membrane and promoting, for 
instance, membrane destabilization, 
then its spectrum of toxicity could be 
much wider. This would turn an unu-
sual cannibalism process into a more 
traditional form of biological warfare. 
A similar wider function can be sug-
gested for the other killing factor, SkfA, 
which is toxic to the rice pathogen 
Xanthomonas oryzae (Lin et al., 2001). 
Whatever the mechanisms of SdpC 
toxicity, it should be stressed that it is 
effective only at high concentrations. 
Therefore, it is safe to predict that it 
operates mostly in colonies (usually 
constituted of siblings) and on mixed 
communities of bacteria, such as 
those existing in natural biofilms.
From its sequence, the SdpI immu-
nity protein is inferred to be an inte-
gral membrane protein. Located in 
the bacterial membrane—the inter-
face between the external medium 
and the cytoplasm—SdpI behaves 
as a receptor (for the SdpC toxin) 
and as a signal transduction protein 
(through its ability to interact with the 
SdpR repressor). Ellermeier et al. 
(2006) isolated two classes of sdpI 
mutants that enabled separation of 
these two functions. Some mutants 
are still immune to SdpC, but they do 
not induce expression of sdpRI in the 
presence of the toxin. These mutants 
appear to have lost the ability to 
interact with SdpR but still recognize 
SdpC. Another class of mutations 
leads to the opposite phenotype, 
with derepression of sdpRI in the 
absence of the SdpC toxin. Evidently, 
these mutations lock the SdpI trans-
ducing protein into the conformation that sequesters SdpR. As these con-
stitutive forms of SdpI confer immu-
nity on the toxin (R. Losick, personal 
communication), they probably still 
interact normally with SdpC.
The mechanism of immunity is a 
matter of conjecture. Assuming that 
SdpI binds directly to SdpC (which 
remains to be demonstrated), the 
simplest model is that trapping of the 
toxin molecules by SdpI is sufficient 
to prevent SdpC from interacting with 
its yet-to-be-identified target. In that 
case, SdpI is an antitoxin which, as is 
commonly the case, induces its own 
synthesis in response to the pres-
ence of the toxin. However, its modus 
operandi is quite peculiar. Membrane 
sequestration is usually designed to 
prevent transcription activation fac-
tors from reaching their DNA targets, 
in prokaryotes as well as in eukaryo-
tes (Alba and Gross, 2004; Brown et 
al., 2000). In the case of SdpI and two 
other bacterial proteins (Bohm and 
Boos, 2004), membrane sequestra-
tion is used to activate transcription 
by trapping a repressor away from the 
genes it controls.
SdpR is an autorepressor that 
blocks transcription of the sdpRI 
operon, but it is likely that this is not 
its sole function. Expression of sev-
eral other operons is dependent on 
SdpR and their products may contrib-
ute to delaying commitment to sporu-
lation (González-Pastor et al., 2003). 
SdpR was also independently identi-
fied in a screen for transposon inser-
tions inhibiting expression of sigW, a 
gene encoding a regulatory protein 
involved in detoxification and antibi-
otic resistance (Turner and Helmann, 
2000). Therefore, the exact scope 
of the SdpR regulon remains to be 
determined. But the results reported 
by Ellermeier et al. (2006) show 
unambiguously that SdpR (and the 
operons it may control) is not involved 
in sensitivity to the SdpC toxin. Like-
wise, SdpR sequestration at the 
bacterial membrane (and its putative 
transcriptional consequences other Cell 124, Fethan induction of sdpI) is not required 
for immunity to SdpC.
Orthologs of the sdpRI operon 
exist in five other Bacillus species, 
with SdpR being strongly conserved 
and SdpI much less conserved. Given 
that these bacteria do not contain an 
ortholog of sdpC, it seems logical to 
propose that an interaction similar 
to that described in B. subtilis takes 
place between their SdpI and SdpR 
orthologs in response to some sig-
nal other than SdpC. This raises the 
intriguing possibility that extracellular 
signals other than SdpC might also 
trigger membrane sequestration of 
SdpR in B. subtilis, thereby activating 
another set of genes and a specific 
response that has yet to be identified. 
The presence in the immediate vicin-
ity of sdpRI of two operons encoding 
ABC transporters might be a clue to 
the identity of these new responses as 
well as to additional extracellular sig-
nals other than SdpC that could affect 
localization of SdpR. We eagerly await 
the results of the next set of experi-
ments characterizing these interest-
ing signaling pathways.
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